Adherium Ltd. (ASK:ADR), which sells a smart inhaler technology in Europe and Australia, is reportedly looking to jump into the direct-to-consumer U.S. market in the first half of this year.
The New Zealand-based company has a deal with AstraZeneca (NYSE:AZN) to combine its Smartinhaler monitoring device with the Symbicort inhaler, but CEO Arik Anderson told MobiHealthNews that he is also looking for other opportunities to penetrate the U.S. market.
Get the full story at our sister site, Drug Delivery Business News.
The post Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech appeared first on MassDevice.